N/A N=110 Addressing Social Determinants of Health & Diabetes Self-Management in Vulnerable Populations
Diabetes
Primary: Percent of Participants With A1C < 8% — 33; 34 percent of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=89 Therapy in Amyotrophic Lateral Sclerosis (TAME)
Amyotrophic Lateral Sclerosis · Frontal Temporal Dementia
Primary: The Primary Comparison for Efficacy Will be Based on a Linear Mixed Effects (LME) Model Fit to the ALSFRS-R Data for the Patients Followed Over 36 Weeks. — -0.290…
Phase 3 N=196 A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Hepatorenal Syndrome
Primary: Percentage of Participants With Confirmed Hepatorenal Syndrome (HRS) Reversal — 19.6; 13.1 percentage of participants
Phase 2 N=413 A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.
Diabetes Mellitus, Type 2
Primary: Absolute Change in HbA1c From Baseline to 16 Weeks — -0.23; -0.91; -1.37; -1.79 percentage (%) of HbA1c — p=<0.0001
N/A N=144 Can Novel Telemedicine Tools Reduce Disparities Related to Early Identification of Autism
Autism Spectrum Disorder · Developmental Delay
Primary: Accurate Diagnosis of Autism Via Telemedicine — 61; 63 Participants
Phase 2 N=14 Pilot Study of Metformin for Patients With Fanconi Anemia
Fanconi Anemia
Primary: Hematologic Response — 4 Participants
Phase 2 N=172 A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia
Friedreich Ataxia
Primary: Change From Baseline in Peak Work (in Watts/kg) During Exercise Testing at Week 12 in Part 1 — 0.14; 0.07; -0.09; 0.06 W/kg — p=0.1524
Phase 2 N=23 Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma
Neoplasms
Primary: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment — 20; 40 Percentage of participants
N/A N=70 Comparative Study of Experimental Dental Adhesive With and Without Phosphoric Acid Pretreatment
Dental Caries
Primary: Color Match — 53; 54; 50; 52 teeth
N/A N=89 Efficacy of Tranexamic Acid for Reducing Blood Loss and Blood Transfusion After Periacetabular Osteotomy
Dysplasia, Congenital Hip
Primary: Calculated Total Blood Loss — 1264.6; 1515.4 mL
Phase 3 N=801 A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders) — 25.1; 49.9 percentage of participants — p=<0.001
N/A N=44 Utilizing Senior Companions to Enhance Dementia Care
Alzheimer Disease · Dementia
Primary: Utilization of LTSS by PWML and Caregivers — 1; 1; 2; 1 Participants
N/A N=20 Osia CPT Code Study
Conductive Hearing Loss · Mixed Hearing Loss
Primary: Change From Baseline in Adaptive Speech in Noise Test Score for Osia 2 System at 3 Months Post-surgery — 6.1 Score on a scale
N/A N=14 Vitamin E Supplementation in Hyperinsulinism/Hyperammonemia Syndrome
Hyperinsulinism-Hyperammonemia Syndrome
Primary: Tolerability of Vitamin E Based on Responses to a Subject/Parent-reported Symptom Questionnaire After Vitamin E Supplementation Compared to Baseline — 2 Participants
Phase 2 N=10 A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer
Breast Cancer
Primary: Number of Patients Experiencing Dose Limiting Toxicity — 10; 0 Participants